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Abstract
Resistin, that was originally discovered in 2001 is named for its capacity to resist insulin action shown mainly in mice. However, 
there is a controversial history regarding its role in the pathogenesis of insulin resistance and type 2 diabetes mellitus (T2DM) 
in humans as most of the research was based on association between resistin blood levels and T2DM or other pathologies and 
so far the pharmacological e!ect of recombinant resistin has not been tested in humans or even in primates. Resistin is a 12 kD 
cysteine-rich small protein acting as covalent dimer.  Although human and mouse resistin genes and protein sequences share 
only approximately 60% homology, which is less than most hormones conserved across species, the genes are syntenic, with the 
mouse gene encoding resistin being located at a similar distance from the insulin receptor gene.  Unlike mouse resistin which 
is mainly expressed in adipocytes, human resistin is synthesized predominantly in monocytes and macrophages, especially in 
the visceral adipose tissue. Resistin’s e!ects are mediated via paracrine and endocrine mechanisms of action through a recep-
tor on the surface of target cells that remains controversial. Others and our study has shown that resistin interacts with the 
Toll-like receptor 4 (TLR4), however other putative receptors such as an isoform of decorin,  mouse receptor tyrosine kinase-like 
orphan receptor 1 (ROR1) and adenylyl cyclase-associated protein 1 (CAP1) have been also proposed.  Downstream targets of 
resistin provide indirect evidence for its function in intracellular pathways, involving impairment of insulin signaling, response 
to in"ammation and proliferation. Despite the lack of in vivo data concerning the resistin receptor and signaling in primates or 
humans, there is a need to explore the in"ammatory, metabolic and oncogenic e!ects of resistin on human diseases. To address 
this challenge we have recently developed resistin mutant (C6A), acting as resistin antagonist which in several in vitro bioassays 
inhibited resistin action and in mice fed high fat diet (HFD) reduced weight, visceral fat, restored insulin sensitivity and attenu-
ated HFD-induced neuroin"amation. 
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Introduction
World Health Organization (WHO) has estimated that more 
than 347 million people worldwide are aected by diabetes and 
more specically type 2 diabetes mellitus (T2DM). In addition 
WHO has also estimated that deaths due to diabetes will in-
crease by two thirds between 2008 and 2030. Despite the enor-
mous progress made to overcome this pathology, its progression 
worldwide is in permanent augmentation. Insulin resistance 
is one of the early features of T2DM, thus, the understanding 
of the mechanisms involved in the onset of insulin resistance 
is crucial for an early intervention circumventing then the es-
tablishment of T2DM. Insulin resistance is associated to several 
metabolic diseases and obesity (1). Obesity is now considered 
as a global epidemic aecting both adults and children, and is 
associated with signicant morbidity and mortality rate and is 
caused by combination of genetic and environmental factors, 
including increased caloric intake, sedentary lifestyle and un-
healthy eating habits. !e prevalence of obesity among children, 
adolescents and adults has been dramatically increased during 
the last several decades. Worldwide, close to two billion adults 
are overweight and over 500 million are obese.  According to 
several epidemiological studies, excessive body weight gain and 
obesity constitute a serious risk factor for insulin resistance 
and type 2 diabetes.  It is also noteworthy that epidemiologi-
cal studies reported that neurodegenerative diseases risk such 
as Alzheimer’s disease (AD) is signicantly increased 50%-100% 
in diabetic cases (2-4). More importantly, insulin resistance is 
now considered as an important etiological factor for AD be-
cause it is associated with reduced insulin-induced activation of 
insulin receptor and subsequent signaling pathways. !us, the 
brain insulin resistance appears to be a common feature of AD 
constituting most likely an early event and marker of the disease. 
In addition, insulin resistance and T2DM are associated with in-
"ammation and neuroin"ammation that further worsen insu-
lin responsiveness. !erefore, developing new therapeutic tools 
to ght insulin resistance is of high priority due to its dramatic 
consequences worldwide. 
Resistin and insulin resistance
Insulin resistance is considered as a common hallmark of many 
metabolic disorders such as T2DM, obesity, dyslipidemias, in-
"ammation, and cardiovascular diseases (1, 5-7). A tremendous 
number of publications have treated this issue in dierent tissues 
and cellular models. One of the puzzling issues concerns the po-
tential link between obesity, in"ammation and insulin resistance. 
Despite the very rich literature concerning insulin resistance, the 
molecular and cellular mechanisms linking obesity and in"am-
mation to insulin resistance are not fully understood.  More es-
pecially, how excessive body weight gain progressively promotes 
insulin resistance is a matter of controversy. Accumulating evi-
dence however suggest that the alteration of whole body insulin 
responsiveness is initiated in the brain and more precisely in the 
hypothalamic nuclei, as hypothalamus is the main brain location 
controlling energy homeostasis by the integration of hormonal 
and metabolic signals responding to the energy body require-
ments. !ese signals mainly originate from adipose tissue (ad-
ipokines) and pancreatic β cells (insulin). Leptin, adiponectin 
and resistin are the major adipokines implicated in the regu-
latory loop involving adipose tissue and the hypothalamus to 
modulate energy homeostasis. !ese adipokines are also strong 
modulators of insulin responsiveness and in"ammation at both 
central and peripheral levels.  Among these adipokines, resistin 
is described as a potential factor in obesity-mediated insulin re-
sistance, T2DM, in"ammation (6, 7). We have recently reported 
that chronic ICV resistin infusion deeply impairs insulin respon-
siveness and signaling in the hypothalamus and peripheral tis-
sues (adipose tissue, liver, muscle) in rats. Additionally, central 
resistin activates the serine kinases Jun NH(2)-terminal kinase 
(JNK) and p38 mitogen-activated protein kinase (p38 MAPK), 
enhances serine phosphorylation of insulin receptor substrate-1, 
and increases the expression of the pro-in"ammatory cytokine 
interleukin-6 (IL-6) in the hypothalamus and key peripheral in-
sulin-sensitive tissues (8).  More importantly, we also reported 
the direct binding of resistin to Toll-like receptor 4 (TLR4) in the 
hypothalamus and showed that this binding activates proin"am-
matory pathways (8). Interestingly, resistin is able to induce the 
phosphorylation of Akt in neuronal cells in vivo (following ICV 
infusion) or in cell culture following short-term stimulation (10 
to 20 minutes). In the same time, infusing resistin ICV during 14 
days led to complete alteration of insulin-dependent Akt phos-
phorylation .  !is is explained by the deep alteration of insulin 
signaling as evidenced by the down-regulation of insulin recep-
tor, the increase of serine phosphorylation of IRS1/IRS-2 and 
the induction of proin"ammatory factors that are also involved 
in the onset of insulin resistance (Fig. 1). Furthermore, ICV in-
fusion of resistin led to the down regulation of insulin receptor 
in liver, muscle and other tissues without signicant changes in 
circulating resistin and this is explained by the vagal connexion 
linking the hypothalamus to the periphery. In term of signaling, 
Akt is down-stream of resistin/TLR4 signaling and also down-
stream of insulin receptor/IRS signaling with probably dierent 
kinetics of action and also with dierent targets. Accordingly we 
hypothesized that resistin/TLR4 Akt pathway will target mainly 
gene expression whereas for insulin it will mainly target meta-
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bolic actions.  Consequently, we concluded that resistin/TLR4 
signaling pathway seems to have a crucial role in the overall 
insulin-resistance and in"ammation onset (8). Targeting this 
signaling pathway may constitute a signicant breakthrough to 
overcome insulin resistance and in"ammation, and related met-
abolic dysfunctions. 
Comparative e!ects of resistin in mice and humans
Accumulating evidence indicates that changes in adipose-se-
creted factors in obesity, including release of in"ammatory 
cytokines, dramatically aect insulin sensitivity (1, 5, 9-12). 
Among these adipokines, resistin is described as a potential fac-
tor in obesity-mediated insulin resistance and T2DM. Resistin 
is a cysteine-rich 12.5 kD polypeptide secreted by adipose tis-
sue in rodents and by macrophages (mainly) in humans (10, 
13), promoting in"ammation and insulin resistance (14-17). 
Circulating resistin is increased in obese insulin-resistant ro-
dents (12, 13) and humans (13) and fasting decreases resistin 
mRNA expression (12, 18). Peripheral administration or trans-
genic overexpression of resistin in rodents impairs insulin ac-
Figure 1. Schematic representation of resistin signaling that leads to inhibition of insulin signaling shown by 5 up-faced arrows: 
cytosolic activation of JNK and p38 kinases leading to serine phosphorylation and subsequent inactivation of IRS-1; nuclear 
activation of NF-kβ and AP-1 leading to enhance expression of IL-6, SOCS-3 and PTB-1B which in turn lead to attenuated activity 
of IRS-1, Akt, ERK 1/2 and dephosphorylation of insulin receptor followed by development of insulin resistance. 
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tion in insulin-sensitive tissues (19-21). Conversely, deletion of 
the resistin gene or infusing of resistin antibodies or antisense 
oligonucleotides restored insulin responsiveness (12, 22-24). 
More recently, it has been shown that resistin is expressed in the 
hypothalamus (25) and activates specic hypothalamic neurons 
(26). Central resistin also modulates glucose homeostasis, lipid 
metabolism, and food intake and impairs liver insulin sensitivity 
(27-30). Resistin also regulates the synthesis and secretion of key 
proin"ammatory cytokines such as tumor necrosis factor-alpha, 
interleukin (IL)-6, and IL-12 in macrophages via a nuclear fac-
tor-kB–dependent pathway promoting insulin resistance (11, 
12, 31, 32). However, whether the results obtained in mice are 
applicable to humans is still puzzling and controversial.  !ough 
some earlier publications questioned the link between resistin 
and insulin resistance in humans [see references 43-48 in (6)] 
our recent screening of the most recent 300 papers in PubMed 
under the term of resistin revealed 20 reports  in which such 
an indirect link, evidenced by resistin levels in serum or tissues 
and various human pathologies such as adiposity, lung injury, 
metabolic syndrome, T2DM, gestational DM, diabetes-induced 
periodontitis, cardiovascular disease (CVD), non-alcoholic fat-
ty liver disease (NFLD) and cancer was demonstrated (33-52). 
!is issue was also widely addressed in the two most recent re-
views.  Abate et al (7) conclude that since in"ammation plays a 
key role in the pathogenesis of T2DM (53) and resistin could be 
implicated in the development of T2DM, via induction of in-
"ammation, adiposity or insulin resistance as shown in (54-56). 
In  T2DM, macrophages, containing the highest levels of resistin 
gene expression (57, 58)  that inltrate the stroma of the adi-
pose tissue and/or the vascular endothelium can locally produce 
and secrete resistin in addition to IL-1β, TNF-α, and IL-6, which 
may enhance the in"ammatory load inducing insulin resistance 
and vascular dysfunction (58). !ough macrophage inltration 
into adipose tissue is a major feature of obesity, and macro-
phages are the main sources of resistin production, yet little is 
known about the dierences in eects between serum and tissue 
resistin levels. Higher resistin levels have also been associated 
with T2DM complications, including renal dysfunction, athero-
sclerosis, gout, CVD, hypertension and peripheral neuropathy 
as shown in references 89-96 in Abate et al (7). Similar summary 
was reached by Park and Ahima in their recent review (6) who 
concluded: “Resistin was initially described as a link between 
obesity and insulin resistance in rodents. In rodents, resistin is 
almost exclusively expressed in white adipocytes, whereas hu-
man resistin is predominantly expressed in macrophages. !e 
phenotypes of humanized resistin transgenic mice (59)  suggest 
similar roles of murine and human resistin in insulin resistance. 
Studies in humanized resistin transgenic mice and epidemiolog-
ical data also suggest that human resistin is a potential mediator 
between in"ammation, and insulin resistance and atherosclero-
sis. Insights into the pathophysiological role of resistin will facil-
itate the development of novel diagnostic and treatment tools for 
diabetes, in"ammation and CVDs”. 
Putative link between insulin resistance and resistin 
polymorphism in humans
Epidemiological studies conducted mainly in Japan linked re-
sistin with insulin resistance and T2DM in humans. Polymor-
phism in the promoter of human resistin gene was positively 
associated with increased resistin levels in circulation (60).  Par-
ticularly the -420 C>G (G/G) genotype at was associated with 
susceptibility to T2DM and also was correlated with monocyte 
resistin expression and with increased serum resistin levels 
(61, 62). Furthermore analysis of over 2000 Japanese subjects 
showed that plasma resistin was associated with SNP -420 and 
also correlated with insulin resistance (63). Similar results re-
ported in a prospective study in China (64) and Egypt (65) but 
not in Korea (66) where the G/G (-420) genotype was associated 
with increased resistin levels but not with T2DM. In contrast, 
other studies were less conclusive: an Italian study showed that 
the presence of -420 C/G SNP is associated with increased obe-
sity and metabolic syndrome but not with resistin levels (67), in 
Caucasian nondiabetic subjects in North America resistin levels 
associated with G/G (-420) genotype but not with insulin re-
sistance (68), wheras in another study no such association was 
detected (69) . So far the origin of those discrepancies remains 
not explained and requires further investigations. 
Interaction of resistin with TLR4 and other putative 
receptors 
!e understanding the biological function of human resistin has 
been so far hampered by lack of information about its corre-
sponding receptor and signaling mechanisms.  In four recent re-
ports several proteins have been suggested as potential receptors 
for resistin:  a TLR4 (70), an isoform of decorin (71), mouse re-
ceptor tyrosine kinase-like orphan receptor 1 (ROR1) (72)  and 
most recently adenylyl cyclase-associated protein 1 (CAP1) (73). 
It was reported that the latter directly binds to human resistin 
and elicits in"ammatory eects in cultured human monocytes 
and in white adipose tissue (WAT) in humanized resistin mice 
in vivo. In contrast both decorin and ROR1 are only putative re-
ceptors for murine resistin, and none of these have been shown 
to mediate the in"ammatory eects of resistin in humans. We 
have demonstrated that at the neuronal level in vivo in rats that 
TLR4 interacts with recombinant human resistin produced in 
our lab and its TLR4-mediated signaling in the hypothalamus 
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lead to the activation of Jun NH2-terminal kinase (JNK) and 
p38 mitogen activated protein kinase (MAPK) signaling path-
ways by the recruitment of the adaptor proteins myeloid dif-
ferentiating factor 88 (MyD88) and Toll/interleukin-1 receptor 
domain containing adaptor protein (TIRAP), promoting over-
all in"ammation and enhancing insulin resistance (8). We have 
also shown that in SH-SY5Y human neuronal cells siRNA-medi-
ated TLR4 knockdown impairs both resistin-induced in"amma-
tory response and insulin resistance (8). Moreover, recent stud-
ies from other labs have provided evidence for the contribution 
of TLR4 in the pathogenesis of obesity and insulin resistance. 
Saturated fatty acids activate both hypothalamic and peripheral 
TLR4 signaling, leading to proin"ammatory cytokine produc-
tion and endoplasmic reticulum stress. Conversely, TLR4 loss-
of-function prevents saturated fatty acid-induced in"ammation 
and insulin resistance (74-77). Resistin and TLR4 have been 
linked to a proin"ammatory process in a human epithelial cell 
line in which resistin competes with lipopolysaccharide (LPS) 
for binding to TLR4 (70). In SH-SH5Y human neuronal cells 
we demonstrated that adiponectin exerts an insulin sensitizing 
eect by improving insulin signaling through recovering of IR 
expression and marked reduction of JNK and IRS-1 phosphory-
lations.  Overexposure of SH-SY5Y cells to resistin induced the 
downregulation of APPL-1 and adiponectin receptors leading 
to the impairment of adiponectin signaling and knock down 
of TLR4 completely abrogated resistin eects on adiponectin 
signaling. !is eect was also veried in vivo where 14 days 
ICV chronic resistin infusion of Wistar rats led to signicant 
down-regulation of hypothalamic APPLL-1 (78). In addition, in 
rheumatoid arthritis disease, resistin has been shown to use the 
IGF-1R signaling pathway. In conclusion, though TLR4 seems 
to be the major resistin receptor, a puzzling situation in which 
resistin could potentially interact with dierent receptors de-
pending upon cellular or in vivo model is still to be considerated.
Development of resistin antagonist 
As formation of covalent resistin dimer C6 bisulde (S-S) bond 
is crucial for its activity (79, 80)  we speculated that mutation of 
C6A may convert resistin to an inactive monomer, or even to re-
sistin receptor antagonist.  !e DNA encoding the ORF mutated 
at C6A was subcloned into pMon vector, and expressed as insol-
uble protein in E. coli (MON 105 strain) upon induction with 
nalidixic acid. Subsequently, insoluble inclusion bodies were 
prepared, solubilized in Tris-buered guanidine in presence of 
reducing agent and refolded by 1:25 slow dilution into oxidiz-
ing solution containing urea, arginine and low concentration 
of cysteine at 4ºC. !en the monomeric fraction was isolated 
to purity by preparative size-exclusion chromatography. Once 
it’s in vitro e&cacy in abolishing resistin-dependent Akt and 
ERK ½ phosphorylation in two types of cells was demonstrated 
it was termed resistin antagonist (RA) (81). Subsequently RA 
treatment of HFD-mice succeeded to reverse completely insu-
lin resistance, to reduce the weight mainly due to reduction of 
visceral fat, to reduce expression of in"ammatory cytokine IL6 
and to attenuate HFD-induced neuro-in"ammation and gliosis. 
In contrast, RA injections to lean mice fed chow diet did not 
aect the sensitivity to insulin, and even slightly (statistically 
borderline) increased their body weight (81) . In view of those 
and others’ results using C6S mutant in lean mice (13)  it seems 
the RA may act dierently in lean and HFD mice. !e reason for 
this is not entirely clear but may be related to the higher levels of 
resistin in the later. 
Conclusions and future directions
 As many of the basic questions related to resistin role in insulin 
intolerance and metabolic syndrome remain unknown, develop-
ment of potent competitive RAs may provide a potent research 
tool for the mechanistic study of resistin in non-genetically ma-
nipulated animals. Furthermore, such antagonist may be thera-
peutically employed to counteract resistin’s pathogenic eects, 
such as those documented in metabolic syndrome, T2DM and 
neuroin"ammation. !erefore, our main research objective is to 
develop a super-active resistin antagonist and to demonstrate 
its activity in various in vivo experiments. For such antagonist 
to be eective, its a&nity to the resistin receptor (TLR4) must 
be considerably higher than that of the native resistin, resulting 
in eective competitive inhibition of resistin action in vivo. To 
achieve this aim it is needed to employ a high throughput tech-
nique, based on repetitive selection of randomly mutated RA 
molecule presented on a yeast surface display library and select-
ed by high-a&nity and avidity binding using repetitive rounds of 
cell sorting as was demonstrated in our preparation of super-ac-
tive leptin antagonists (82). Furthermore to test the in vivo eec-
tiveness of the RA and it high-a&nity, putatively superactive RA 
there is a need to prepare its mono-pegylated analogue which 
will extend its in vivo half-life in circulation. Such development 
of the recombinant high a&nity RA may provide new and sig-
nicant research and therapeutic advantages: (i) high through-
put screening for structurally important binding motifs will ex-
tend our knowledge about resistin-TLR4 interactions, and (ii) 
the high a&nity RA is expected to become an important new 
research tool in the eld of metabolic syndrome biology, by al-
lowing for the rst time for potent and reversible inhibition of 
resistin. In vitro studies using the new molecules will enable the 
mechanistic study of downstream resistin eects on a variety of 
cells and tissues. In vivo, the superactive RA will enable the sys-
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tematic study by blocking of the eects of endogenous resistin in 
non-genetically manipulated animals. !e high a&nity binding 
of the superactive RA will enable to achieve eective peripher-
al and central resistin inhibition in tolerable antagonist doses, 
using non-genetically modied animal models. Also, (iii) such 
new knowledge will enable future utilization of RA to modulate 
pathologic situations in which local or systemic resistin activity 
has been convincingly shown to play pathological role such as 
cancer and CVD. !ough the later  aspects of resistin function 
are not covered in the present review, blocking resistin action 
maybe highly benecial in several types of malignancy as sum-
marized in recent reviews (83-86) and in ameliorating elevated 
serum low density lipoprotein and thereby atherosclerotic CVD 
in obese humans (87-89). 
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